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to support consistent reporting of dose-volume data and 
NTCP-models. However, further improvement of delineation 
quality can be achieved by training and education, and a 
more consistent use of these guidelines. References: 1. 
Brouwer et al., Radiother Oncol 2015 aug 13 (ahead of print). 
2. Steenbakkers et al., Int J Radiat Oncol Biol Phys. 
2006;64:435-48. 3. Hanna GG et al., Clin Oncol. 2010;22:515–
525. 
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Locally advanced NSCLC is a heterogeneous disease both with 
regard of the staging and the tumor behavior. In order to 
improve outcome, combinations of radiation (RT) with 
cytotoxic drugs to modulate RT-induced cytotoxicity were 
introduced and are now standard of care. Also in many other 
malignancies combined modality has shown to improve 
outcome and has become standard of care. These treatment 
options are in particular of benefit in patients that can 
tolerate such treatment regimens. Improvements have been 
made both in chemotherapy and the radiotherapy. However, 
co-morbidities and the observed increased normal tissue 
toxicity limit the use of potent chemoradiotherapy 
approaches. In order to enhance the therapeutic window, 
tumor targeted strategies are needed to allow tumor 
radiosensitization while not affecting normal tissue. This 
warrants the evaluation of the potential of novel targeted 
radiosensitizers with tumor targeted properties. The main 
mechanism by which both radiation and cisplatin kill tumor 
cells is by an accumulation of un- or misrepaired DNA 
damage. PARP inhibitors increase radiation and 
chemotherapy (cisplatin) response in preclinical studies 
including lung cancer models. PARP inhibitors have been 
shown to specifically kill homologous recombination deficient 
tumor cells as single agent. ATM mutations are expected to 
affect DSB repair and homologous recombination status 
therefore amplifying damage induced by the combined PARP 
inhibitor radiation treatment. Thus tumor targeted treatment 
and radio-chemosensitization in lung cancer could be 
achieved in the presence of frequently observed ATM gene 
mutations in lung cancer. Olaparib exhibits low systemic 
toxicity profiles when given as monotherapy. When combined 
with cisplatin and RT enhanced toxicity is anticipated, 
necessitating careful dose- and schedule-finding and 
development and validation of supporting pharmacodynamic 
markers. Such approach could also serve as a template for 
other promising radiosensitizers, for example DNA-PK, ATM 
and ATR inhibitors of kinases that are key mediators of the 
so-called DNA damage response (DDR). 
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Increased understanding of the molecular mechanisms 
underlying tumour and normal cell radiosensitivity has led to 
the identification of a variety of potential targets for rational 
intervention. These are based on the “hallmarks of cancer”, 
eight biological capabilities acquired during the multistep 
development of human tumours. Among these, targeting the 
DNA damage response represents an attractive strategy, 
especially in tumours that contain mutations in specific 
components of the DNA repair pathway, such as BRCA1 and 
BRCA2. In addition to their use as single agents, inhibitors of 
the DNA damage response, when combined with radiation 
could increase tumour response while sparing the normal 
tissue. 
Poly(ADP-ribose) polymerase (PARP) inhibitors affect DNA 
repair and thus are good candidates for combined use with 
DNA damaging agents. Indeed, PARP inhibitors increase 
radiation and chemotherapy responses in preclinical studies. 
As a single agent they have been shown to specifically kill 
homologous recombination (HR) deficient tumour cells. A 
large variety of tumour-specific mutations, such as in BRCA or 
ATM, affect double strand break repair and HR status and 
therefore amplify the damage induced by the combined PARP 
inhibitor radiation treatment. We found that the PARP 
inhibitor olaparib induced radiosensitisation in mouse breast 
cancer cells and in a panel of human head and neck cancer 
cell lines at much lower doses than those required for its 
single agent activity. Importantly, at these low doses olaparib 
prevented PAR induction by radiation. Also, the extent of 
radiosensitisation by olaparib depended on the integrity of 
the HR pathway, as witnessed by the difference in olaparib 
dose required to induce radiosensitisation in BRCA2-deficient 
versus BRCA2-complemented cells. 
We have designed 3 phase I-II studies evaluating the safety 
and tolerability of olaparib, in combination with radiotherapy 
in locally advanced breast cancer, non-small cell lung cancer 
and head and neck cancer. Dose-escalation according to the 
TITE-CRM design allows the evaluation of late toxicity and 
ensures continuous patient accrual. In support of these trials, 
biomarkers for the radiosensitisation efficacy of PARP 
inhibitors have been developed and are evaluated. Tumour 
and normal tissue samples are collected from all patients to 
measure PARP inhibition and γH2AX foci formation. These 
measurements will help to guide the dose-escalation strategy 
used in these trials. 
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DNA repair within cancers contributes to radioresistance and 
is a concept across all histology’s. Cancer cells employ rapid 
and efficient methods for repairing damaged single and 
double strand DNA breaks from radiation and chemotherapy. 
Can we take advantage of this survival mechanism? One 
strategy incorporates the use of poly(ADP-ribose) polymerase 
(PARP) inhibitors. What do we know about PARP? PARP 
inhibition sparked interest in oncology based in part on the 
concept of “synthetic lethality” in which cancer cells with 
pre-existing deficiencies in homologous-recombination 
pathways (e.g. BRCA mutations) exhibit highly selective 
cytotoxicity to single agent PARP inhibitors in contrast to 
normal cells – a differentiation that radiation oncologists find 
attractive and might provide an opportunity with radiation 
based studies for locally advanced cancers. Building upon the 
synthetic lethality story, PARP inhibitors show promise as 
radiosensitizers by directly preventing cancer cells from 
repairing stress induced DNA damage. In the preclinical 
setting, our data suggested enhanced sensitivity to PARP(I) 
monotherapy as well as when combined with radiation across 
a variety of HNSCC lines known to be HPV negative many 
groups have shown the ability of PARP inhibitors to sensitize 
a variety of histology’s, both p53 wild type and null, to 
radiation in both in vitro and in vivo settings. The data seems 
to suggest that the levels of PARP inhibition required to 
enhance radiation may be significantly lower than when used 
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as a monotherapy. Remarkable activity has been observed in 
patients with BRCA1/2 mutations using Olaparib (AZD2281), 
an orally bioavailable PARP inhibitor, recently approved for 
refractory ovarian cancer with BRCA1/2 mutations. Toxicity 
with monotherapy has been remarkably low. Is the BRCA 
mutation story the only predictor of PARP inhibition (I) 
sensitivity? Perhaps other homologous and non-homologous 
repair defects may also contribute to PARP(I) sensitivity. 
Fanconi anemia phenotypes may also relate to sensitivity as 
well as pathways related to the SMAD family. We assessed 
the safety, toxicity and early response when combining 
escalating doses of Olaparib with fixed dose cetuximab and 
RT in heavy smoker HNSCC patients. We chose this group of 
patients due to their high local-regional failure rates and 
hypothesized amplified rates of HR defects that would lend 
itself to Olaparib sensitivity. We used a TITE-CRM model with 
a starting Olaparib dose of 50 mg po BID. The TITE-CRM 
algorithm uses both the length of observation and whether or 
not a DLT has occurred in each previous patient enrolled on 
the trial to estimate the probability of a DLT for each dose 
level, thereby optimizing subsequent dose assignment. We 
enrolled 13 patients to date. Among these patients, with a 
median follow-up of ~14 months, two failed distantly and one 
failed locally. Patients who experienced local/regional 
failures continued to smoke during treatment. Toxicity was 
primarily related to grade 3 dermatitis and acneiform rash. 
Skin toxicities resolved in all patients after treatment 
concluded; long-term follow up has revealed development of 
grade 2 fibrosis in the neck areas where dermatitis was most 
severe in four patients. The optimal timing of PARP inhibitors 
and radiation remains unknown and with dose enhancement 
factors seen pre-clinically, might it be possible to investigate 
radiation de-intensification or perhaps consider novel 
combinations with checkpoint inhibitors. This discussion will 
include a review of some of the pertinent pre-clinical studies 
with radiation, a review of toxicities and cautions as it 
relates to combinations with radiation and what are the 
possibilities for future approaches with DNA repair in locally 
advanced disease. 
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The α-β ratio for prostate cancer (PCa) is postulated to be 
low; < 3 Gy, i.e. even lower than for late normal tissue 
reactions. Hence hypofractionated radiotherapy (RT) is 
hypothesized to be advantageous for treatment of localized 
PCa. Literature data indicating that this is the case for a 
moderately hypofractionated regimen was first reported from 
Italy by Arcangeli. This study was however quite small. At 
ECC 2015 Dearnaley presented the results from the UK three-
armed CHHiP-trial comprising 3,200 patients. This three-
armed trial showed non-inferiority between the 74 Gy 
conventional arm (37 fr; 2 Gy/fr) and the 60 Gy moderately 
hypofractionated arms (20 fr; 3 Gy/fr) while the 
experimental arm given 57 Gy arm (19 fr; 3Gy/fr.) had lower 
efficacy. Patients had predominately intermediate risk 
tumours and most patients received 6 month of neoadjuvant 
and concomitant castration treatment. Previously published 
toxicity data from the trial showed similar results for the 
trial arms. Results from other moderately hypofractionated 
schedules have also been reported recently. RTOG 0415 with 
only low-risk patients, showed that 70 Gy in 28 fr over 5.6 
weeks is non-inferior to 73.8 Gy in 41 fr over 8.2 weeks for 
low risk PCa patients. The Dutch randomised phase III HYPRO 
trial with 804 evaluable patients with intermediate/high-risk 
PCa, comparing moderately hypofractionated RT (19 fr; 3.4 
Gy/fr.) with conventional RT (39 fr; 2 Gy/fr), showed non-
inferiority with comparable toxicity.  
Some prospective results of Sterotactic Body RadioTherapy 
(SBRT) with 5 fractions and 7-8 Gy/fr suggest equal clinical 
outcome compared to conventional RT and with acceptable 
toxicity. The Scandinavian multicentre phase III trial “HYPO-
RT-PC” was recently closed, with 1200 patients recruited 
during 2005-2015. All patients had intermediate risk PCa 
(PSA≤20; one or two of the risk factors; T3, Gleason ≥7, PSA 
10-20). No hormones were used. Patients were randomized to 
either conventionally fractionated RT (39 fr; 2.0 Gy/fr) over 
7 weeks, or to a schedule with extreme hypofractionation (7 
fr; 6.1 Gy/ fr) in 2.5 weeks (always including two weekends). 
The two treatment arms are designed to be equieffective for 
late normal tissue complications assuming α/β=3 Gy. Primary 
endpoint will be mature within 2 years, and toxicity data will 
be reported by late this year. 
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Brachytherapy has always represented the most focal means 
on delivering radiationh having the advantages of the inverse 
square law around the radiation source which ensures 
delivery of an intense high dose within the implant and a 
rapid fall dose outside. These characteristics mean that 
brachytherapy can deliver very high doses to the prostate 
gland with in the tolerance doses of bladder and rectum and 
that the characteristics of dose distribution with in the 
implant mean that the volume receiving 150% and 200% 
prescribed peripheral dose (the 150 and the 200) are 
considerably greater than can be achieved with any external 
beam technique.  
Brachytherapy as a boost can be used in two distinct ways. 
First is as a boost to the whole gland following external beam 
radiotherapy. There is now grade a level I evidence from 
randomised controlled trials that both low dose rate and high 
dose rate brachytherapy achieve effective dose escalation 
and consequently better biochemical relapse free survival.  
There is also increasing interest in the use of brachytherapy 
to deliver a focal boost to dominant lesions defined on multi-
parametric MR scanning and mapping template biopsies. Thus 
within a whole gland brachytherapy volume sub volumes can 
be defined within which the dose can be further escalated. 
Planning studies have confirmed the feasibility of this 
approach with both low dose rate and high dose rate 
brachytherapy and the requirements for catheter or seed 
placement to achieve these endpoints has been described. 
The clinical application of this approach is still in its infancy 
although early results confirm its feasibility.  
Summary: both low dose rate and high dose rate 
brachytherapy offer optimal means of focal dose delivery 
within the prostate gland. The use of this modality for whole 
gland treatment is now well established sound evidence base. 
Emerging application sub volume posts to dominant tumour 
volumes is under investigation. 
 
 
 
 
 
 
